Patient HLA-DRB1* and -DQB1* allele and haplotype association with hepatitis C virus persistence and clearance

Ali, Lubna; Mansoor, Atika; Ahmad, Nafees; Siddiqi, Saima; Mazhar, Kehkashan; Muazzam, Ambreen Gul; Qamar, Raheel; Khan, Khalid

doi:10.1099/vir.0.018119-0

Cited by 31 publications

(28 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These findings were also supported by a cohort study on Pakistani HCV patients treated with IFN therapy which reported that HLA-DRB1*07 individually or in combination with HLA-DQB1*02 was associated with viral persistence, however unlike our results, HLA-DRB1*11 was found to be associated with viral clearance (Ali et al, 2010). In addition, in the Polish population, HLA DRB1*07 and DRB1*13 were more frequent in non-responders and responders to treatment respectively, but without statistical significance (Piekarska et al, 2002).…”

Section: ) -------------------------------------------------------contrasting

confidence: 40%

The Association of HLA Class II Alleles with the Response to Alfa-Interferon/Ribavirin Therapy in Chronic Hepatitis C Patients

Gawish¹,

Mohammed²,

Hussein³

et al. 2015

American Journal of Immunology

View full text Add to dashboard Cite

Human Leucocyte Antigens (HLA) class II appears to play an important role in the individual's immune response to viral infection. The present study was aimed at assessment of the relationship between HLA DRB1 alleles and the response to HCV combined therapy in Chronic Hepatitis C patients (CHC). We enrolled a total of 44 chronically infected HCV patients without Hepatitis B Virus (HBV) or Human Immunodeficiency Virus (HIV). Their mean age was 36.45±11.18 years (21-63). HLA-DRB1 typing was done by real time Polymerase Chain Reaction (PCR). ALT and Hemoglobin (Hb) levels were assessed as well as viral genotype was taken from patients' reports (HCV genotypes were 1, 2, 3 and 4 representing 13.6, 13.6, 4.5 and 68.18%, respectively). The most frequent alleles demonstrated among patients were DRB1*13 and DRB1*07 (31.8 and 36.4%, respectively). Analysis of DRB1 frequency between sustained responders and non responders revealed that DRB1*13 allele was significantly higher among sustained responders (p<0.001), while DRB1*07 allele was significantly higher among non responders (p<0.01). Female sex, HCV genotype 2 and pretreatment low serum HCV RNA level were associated with Sustained Virological Response (SVR). Also, elevated Alanine aminotransferase (ALT) level at the 1st week of therapy followed by return to baseline level at the 4th week and a decrease of the mean hemoglobin concentration at 4th week and 12th week of therapy were significantly associated with SVR. We concluded that the virological and special HLA patterns may possibly predict the response to combination therapy in CHC patients.

show abstract

Section: ) -------------------------------------------------------contrasting

confidence: 40%

The Association of HLA Class II Alleles with the Response to Alfa-Interferon/Ribavirin Therapy in Chronic Hepatitis C Patients

Gawish¹,

Mohammed²,

Hussein³

et al. 2015

American Journal of Immunology

View full text Add to dashboard Cite

show abstract

“…In summary, it is obvious that none of the host factors studied to date can be used as the sole predictive factor for response to therapy in actual clinical settings. As other polymorphisms were found in the genes of HCV-infected patients, they were shown to be associated with viral persistence or clearance; the HLA-DRB1*07 allele was found to be significantly associated with virus persistence, and HLA-DQB1*0301 was found to be associated with virus clearance [33]. Also, IL12B 3'-UTR 1188-Callele carriers appeared to be capable of responding more efficiently to antiviral combination therapy as a consequence of a reduced relapse rate [34].…”

Section: Discussionmentioning

confidence: 88%

Relation of interleukin-1β gene to treatment response in chronic patients infected with HCV genotype 4

Omran

Ibrahim

Youssef

et al. 2013

J Infect Dev Ctries

View full text Add to dashboard Cite

Introduction: Hepatitis C virus (HCV) infection results in chronic hepatitis in more than 70% of infected patients, while 20-30% of patients recover spontaneously. This strengthens the role of the host genetic factors in either spontaneous or drug-induced viral clearance. The aim of this study was to investigate the relationship between interleukin-1β +3953 gene polymorphism and the response to interferon therapy in chronic HCV patients infected with genotype 4. Methodology: The interleukin-1β (+3953 C/T) (rs1143634) gene was amplified in 115 chronic HCV patients. Interleukin-1β single nucleotide polymorphism (SNP) plus several clinical and pathological factors were statistically analyzed in correlation with response to therapy. Results: Genotypes C/T and T/T had a significant association with non-response to treatment compared to genotype C/C, which had a strong association with response to treatment (95% confidence; 6.4884-48.5818, p = 0.0001). Furthermore, analysis of allele frequency in this cohort revealed that the T allele is associated with non-response, higher fibrosis, and higher hepatic activity, while the C allele had a significant association with sustained virologic response lower fibrosis, and lower hepatic activity (p value = 0.0001). Conclusion: This is the first study to examine the correlation between interleukin-1β (+3953 C/T) (rs1143634) gene polymorphism and the response of interferon therapy in genotype 4 HCV-infected patients. The results encourage further assessment of this SNP as a marker to predict response to therapy and disease progression, which can have major implications in saving money, time, and in avoiding unnecessary adverse effects.

show abstract

“…were less likely to achieve SVR than carriers of DQB1*0301 (OR 0.32 [41]). The picture is completed by several reproduction failures [42][43][44].…”

Section: Major Histocompatibility Complexmentioning

confidence: 93%

The pharmacogenetic background of hepatitis C treatment

Schlecker¹,

Ultsch²,

Geißlinger³

et al. 2012

Mutation Research/Reviews in Mutation Research

View full text Add to dashboard Cite

Patient HLA-DRB1* and -DQB1* allele and haplotype association with hepatitis C virus persistence and clearance

Cited by 31 publications

References 46 publications

The Association of HLA Class II Alleles with the Response to Alfa-Interferon/Ribavirin Therapy in Chronic Hepatitis C Patients

The Association of HLA Class II Alleles with the Response to Alfa-Interferon/Ribavirin Therapy in Chronic Hepatitis C Patients

Relation of interleukin-1β gene to treatment response in chronic patients infected with HCV genotype 4

The pharmacogenetic background of hepatitis C treatment

Contact Info

Product

Resources

About